
Amphista Therapeutics raises $7.5m Series A round to advance targeted protein degradation assets in cancer
Amphista Therapeutics, a biopharmaceutical company creating first-in-class cancer therapeutics that harness the body’s natural processes to selectively and efficiently degrade...